Uterus transplantation trial 1 year outcome

Nine women with uterine factor infertility underwent live-donor uterus transplantation. The seven cases with viable uteri after 12 months are presented, with special reference to menstruation, blood flow, rejection, and immunosuppression.

Like Comment

Authors

Liza Johannesson, M.D., Ph.D., Niclas Kvarnström, M.D., Johan Mölne, M.D., Ph.D., Pernilla Dahm-Kähler, M.D., Ph.D., Anders Enskog, M.D., Ph.D., Cesar Diaz-Garcia, M.D., Michael Olausson, M.D., Ph.D., Mats Brännström, M.D., Ph.D.

Volume 103, Issue 1, Pages 199-204

Abstract

Objective:

To report the 12-month outcome of seven patients with viable uteri after uterus transplantation (UTx).

Design:

Prospective observational study.

Setting:

University hospital.

Patient(s):

Seven patients with absolute uterine infertility and viable uteri for 12 months after live-donor UTx.

Intervention(s):

Predetermined immunosuppression was with tacrolimus and mychophenolate mofetil (MMF) during 6 months, whereupon MMF should be withdrawn. Frequent ultrasound examinations were performed to assess uterine appearance and uterine artery blood flow. Cervical biopsies (for histological detection of rejection) were obtained at preset time points, with temporary adjustments of immunosuppression if there were signs of rejection. Menstruations were systematically recorded.

Main Outcome Measure(s):

Menstruation, uterine artery blood flow, histology of cervical biopsies, and blood levels of tacrolimus.

Result(s):

All patients showed regular menses after 1–2 months. Uterine artery blood flow was unchanged, with a median pulsatility index of 1.9 (range, 0.5–5.4). Blood levels of tacrolimus were approximately 10, 9, and 8 (μg/L) during months 2, 9, and 12, respectively. Four recipients showed mild inflammation in biopsies after MMF withdrawal and were treated with corticosteroids and azathioprine during the remainder of the 12 months. Subclinical rejection episodes were detected on ectocervical biopsies in five recipients. Histology showed apoptotic bodies and occasional spongiosis in the squamous epithelium. Moderate infiltration of lymphocytes and neutrophils was seen in the epithelial/stromal interface. All rejection episodes were successfully treated for 2 weeks with corticosteroids or dose increments of tacrolimus.

Conclusion(s):

We demonstrate long-term uterine viability after UTx, with continued menstruation and unaltered uterine artery blood flow. Subclinical rejection episodes were effectively reversed by temporary increase of immunosuppression.

Clinical Trial Registration Number:

NCT01844362.

Read the full text at: http://www.fertstert.org/article/S0015-0282(14)02201-8/fulltext


Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.